Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
64.310,83
2,26%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Replimune Group Inc (REPL) Replimune Group Inc (REPL) Notizie

Replimune Group Inc

REPL
6,95
0,39 (5,95%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/4/202423:00GLOBEInterim Results from the ARTACUS Clinical Trial of RP1..
04/4/202414:00GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
26/3/202412:30GLOBEReplimune Announces Appointment of Sushil Patel to CEO and..
06/3/202414:00GLOBEReplimune to Present at the American Association for Cancer..
05/3/202414:00GLOBEReplimune to Present at Three Upcoming Investor Conferences
14/2/202413:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202414:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/2/202414:05EDGAR2Form 8-K - Current report
08/2/202414:00GLOBEReplimune Reports Fiscal Third Quarter 2024 Financial..
16/1/202410:06PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
16/1/202409:59PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
08/1/202414:00EDGAR2Form 8-K - Current report
28/12/202314:00GLOBEReplimune to Present at the 42nd Annual J.P. Morgan..
26/12/202323:15EDGAR2Form 8-K - Current report
05/12/202313:19EDGAR2Form 8-K - Current report
05/12/202313:00GLOBEReplimune Shares Initial Primary Analysis Results from..
18/11/202302:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/11/202302:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202315:10GLOBEReplimune Presents Updated Data on RP2 in Uveal Melanoma..
07/11/202323:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202314:15EDGAR2Form 8-K - Current report
07/11/202314:00GLOBEReplimune Reports Fiscal Second Quarter 2024 Financial..
04/11/202300:30GLOBEReplimune Presents Updated Interim Results from the ARTACUS..
21/9/202302:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202302:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
19/9/202322:01GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
19/9/202314:15EDGAR2Form 8-K - Current report
19/9/202314:00GLOBEReplimune Announces Appointment of Emily Hill as Chief..
14/9/202303:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202315:17EDGAR2Form 8-K - Current report
25/8/202302:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202302:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202315:04EDGAR2Form 8-K - Current report
03/8/202314:45EDGAR2Form S-3ASR - Automatic shelf registration statement of..
03/8/202314:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202314:09EDGAR2Form 8-K - Current report
03/8/202314:00GLOBEReplimune Reports Fiscal First Quarter 2024 Financial..
01/8/202314:00GLOBEReplimune to Present at Two Upcoming Investor Conferences
31/7/202322:01BWReplimune and Incyte Enter into Clinical Trial Collaboration..
27/7/202302:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
26/7/202323:08EDGAR2Form ARS - Annual Report to Security Holders
26/7/202323:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26/7/202323:02EDGAR2Form DEF 14A - Other definitive proxy statements
20/7/202314:56EDGAR2Form 8-K - Current report
20/7/202314:00GLOBEReplimune Announces Sander Slootweg will Depart from its..
12/7/202303:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202322:27EDGAR2Form 144 - Report of proposed sale of securities
06/6/202316:00GLOBEReplimune Presents Initial RP1 Data from the ARTACUS..
05/6/202314:00GLOBEReplimune Appoints Veleka R. Peeples-Dyer to its Board of..
03/6/202320:15GLOBEReplimune Presents RP1 Data from the IGNYTE anti-PD1 Failed..
Apertura: 6,80 Min: 6,605 Max: 7,08
Chiusura: 6,56

La tua Cronologia

NASDAQ
REPL
Replimune
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network